Primary Site >> Pancreatic Cancer
Gene >> ERBB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: The c-erb B-2 proto-oncogene in human pancreatic cancer. PMID: 2202801 |
Ref: Expression of c-erbB-2 in human pancreatic adenocarcinomas. PMID: 1675057 |
Ref: The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. PMID: 1347773 |
Ref: [Gene expression of TGF alpha, TGF beta 1 and C-erbB2 oncogene in human pancreatic carcinoma cell lines]. PMID: 7909745 Ref: Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. PMID: 8096502 Ref: Overexpression of HER2/neu oncogene in human pancreatic carcinoma. PMID: 8104858 Ref: Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. PMID: 8105469 |
Ref: Gene therapy for cancer using tumour-specific prodrug activation. PMID: 7584078 Ref: Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. PMID: 7820300 Ref: HER2/neu immunostaining in pancreatic carcinoma. PMID: 7911120 Ref: Expression of EGF, TGF-alpha, EGFR and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. PMID: 7947634 |
Ref: Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. PMID: 7594766 Ref: Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. PMID: 7637957 Ref: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. PMID: 7653991 Ref: Oncogenes in cancer of the pancreas. PMID: 7781791 |
Ref: Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. PMID: 8617452 Ref: Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. PMID: 8683379 Ref: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. PMID: 8834768 |
Ref: HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. PMID: 9094152 Ref: Hepatobiliary and pancreatic mucinous cystadenocarcinomas with mesenchymal stroma: analysis of estrogen receptors/progesterone receptors and expression of tumor-associated antigens. PMID: 9110301 Ref: The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. PMID: 9174600 Ref: Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells. PMID: 9288128 Ref: Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. PMID: 9322121 Ref: The molecular genetics of pancreatic cancer. PMID: 9364657 Ref: Differential oligonucleotide activity in cell culture versus mouse models. PMID: 9383573 |
Ref: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. PMID: 9485028 Ref: An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. PMID: 9563882 Ref: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. PMID: 9665487 Ref: Novel approaches in development for the treatment of pancreatic cancer. PMID: 9792896 Ref: HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia. PMID: 9798411 Ref: The molecular and cellular biology of pancreatic cancer. PMID: 9807701 Ref: Current concepts in pancreatic cancer: symposium summary. PMID: 9821173 Ref: Pancreatic cancer and fibrinogen storage disease. PMID: 10193333 |
Ref: Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. PMID: 10029438 Ref: Role of tumour markers, cytogenetics. PMID: 10436809 Ref: Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. PMID: 10470176 Ref: Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. PMID: 10615931 Ref: [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma]. PMID: 10909469 |
Ref: Current approaches and future strategies for pancreatic carcinoma. PMID: 10830140 Ref: Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. PMID: 11701553 |
Ref: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). PMID: 11331475 Ref: An immunostaining panel for diagnosis of malignancy in mucinous tumors of the pancreas. PMID: 11371228 Ref: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. PMID: 11406567 Ref: Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas. PMID: 11462947 Ref: Novel therapies for pancreatic cancer. PMID: 11561610 Ref: Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. PMID: 11583287 Ref: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. PMID: 11586103 Ref: [Tumor antigens presented to T helper lymphocytes--critical components of the cancer vaccine]. PMID: 11715777 Ref: Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. PMID: 11751405 |
Ref: HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. PMID: 11807625 Ref: Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. PMID: 12055597 Ref: Palliative MEFLEP therapy in advanced pancreatic cancer: excellent response in a patient with Her-2/neu amplification. PMID: 12131783 Ref: Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. PMID: 12168842 Ref: Fas and Fas ligand expression in pancreatic adenocarcinoma. PMID: 12370548 Ref: Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. PMID: 12378529 Ref: Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes. PMID: 12530087 Ref: Future directions in the treatment of pancreatic cancer. PMID: 12577231 Ref: Minute invasive ductal carcinoma of the residual pancreas after distal pancreatectomy for intraductal papillary-mucinous tumor. PMID: 12622431 Ref: Drug development in pancreatic cancer: finally, biology begets therapy. PMID: 12794245 |
Ref: Preclinical studies with Erlotinib (Tarceva). PMID: 12840797 Ref: HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. PMID: 12894556 Ref: Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. PMID: 12942124 Ref: Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. PMID: 14519649 Ref: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. PMID: 14520413 Ref: Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. PMID: 14586404 Ref: Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. PMID: 14647146 Ref: Surveillance for familial pancreatic cancer. PMID: 14743890 |
Ref: Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. PMID: 14744777 Ref: [Recent advances in gene change of pancreatic cancer]. PMID: 15052782 Ref: Correlation of immunohistochemically detected HER-2/neu (c-erbB-2) with histological stage and perineural invasion in pancreatic cancer. PMID: 15086152 Ref: Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules. PMID: 15166675 Ref: A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. PMID: 15184872 Ref: Identification and characterization of human DFNA5L, mouse Dfna5l, and rat Dfna5l genes in silico. PMID: 15289881 Ref: ErbB2 oncogene antibodies differentiate between the normal and diseased pancreas, and between chronic pancreatitis and pancreatic cancer. PMID: 15547756 Ref: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. PMID: 15581051 Ref: Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. PMID: 15585383 Ref: Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. PMID: 15585615 Ref: [(11)C]N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine PMID: 20641864 |
Ref: Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. PMID: 15734212 Ref: A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment. PMID: 15762277 Ref: ErbB2 growth factor receptor, a marker for neuroendocrine cells? PMID: 15775699 Ref: Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. PMID: 15801978 Ref: Human archival tissues provide a valuable source for the analysis of spatial genome organization. PMID: 15827756 Ref: Small molecules with EGFR-TK inhibitor activity. PMID: 15857287 Ref: From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. PMID: 15864214 Ref: Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. PMID: 15879625 Ref: Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. PMID: 15987444 Ref: Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. PMID: 16142331 Ref: Molecular prognostic markers in pancreatic cancer: a systematic review. PMID: 16146690 Ref: Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. PMID: 16183479 Ref: Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. PMID: 16248771 Ref: Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. PMID: 16373709 |
Ref: Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo. PMID: 15891882 Ref: Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. PMID: 16480284 Ref: Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. PMID: 16489645 Ref: Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. PMID: 16940943 |
Ref: Expression and differential signaling of heregulins in pancreatic cancer cells. PMID: 17096356 Ref: Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. PMID: 17234748 Ref: [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas]. PMID: 17493384 Ref: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. PMID: 17545543 Ref: Overexpression of ErbB2 in the exocrine pancreas induces an inflammatory response but not increased proliferation. PMID: 17546589 Ref: Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. PMID: 17611667 Ref: Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. PMID: 17671194 Ref: Histologic and immunohistochemical changes in the stented common bile duct. PMID: 17721275 Ref: [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer]. PMID: 17937885 Ref: [Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]. PMID: 17964979 |
Ref: Pancreatic cancer and the FAMMM syndrome. PMID: 17992582 Ref: The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. PMID: 18082672 Ref: Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. PMID: 18171715 Ref: [Future directions of anticancer drug development in Japan]. PMID: 18281781 Ref: MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. PMID: 18381409 Ref: HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. PMID: 18463983 Ref: Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. PMID: 18492726 Ref: Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. PMID: 18505086 Ref: Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. PMID: 18528301 Ref: Pancreatic cancer: a plea for good and comprehensive morphological studies. PMID: 18617774 Ref: Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells. PMID: 18820370 Ref: Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. PMID: 18974138 |
Ref: Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. PMID: 18813127 Ref: The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. PMID: 19029090 Ref: A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. PMID: 19133157 Ref: A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. PMID: 19188163 Ref: Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. PMID: 19276352 Ref: HER2 overexpression correlates with survival after curative resection of pancreatic cancer. PMID: 19432892 Ref: The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. PMID: 19435870 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. PMID: 19720778 Ref: Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. PMID: 19738614 Ref: Monoclonal antibodies in the treatment of pancreatic cancer. PMID: 20046965 Ref: Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma. PMID: 20430737 |
Ref: Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. PMID: 19889608 Ref: In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. PMID: 19925494 Ref: Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. PMID: 20103665 Ref: Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. PMID: 20116405 Ref: Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. PMID: 20143778 Ref: Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? PMID: 20459551 Ref: Cistaceae aqueous extracts containing ellagitannins show antioxidant and antimicrobial capacity, and cytotoxic activity against human cancer cells. PMID: 20510328 Ref: Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. PMID: 20534909 Ref: Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kappaB activation in breast and pancreatic tumor cells. PMID: 20699088 Ref: Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. PMID: 20717927 Ref: Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. PMID: 20798912 Ref: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. PMID: 20847288 |
Ref: Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. PMID: 20725099 Ref: Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. PMID: 21110957 Ref: Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. PMID: 21169024 Ref: A novel tumor-associated pancreatic glycoprotein is internalized by human dendritic cells and induces their maturation. PMID: 21346236 Ref: RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. PMID: 21470770 Ref: Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. PMID: 21550422 Ref: Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. PMID: 21723941 Ref: Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. PMID: 22064683 Ref: Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival. PMID: 22870146 Ref: Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. PMID: 24757739 |
Ref: MUC13 mucin augments pancreatic tumorigenesis. PMID: 22027689 Ref: Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. PMID: 22213458 Ref: Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. PMID: 22374460 Ref: The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PMID: 22393391 Ref: In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. PMID: 22431920 Ref: Targeting EGFR in pancreatic cancer treatment. PMID: 22458527 Ref: KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. PMID: 22589274 Ref: Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. PMID: 22642827 Ref: Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PMID: 22761868 Ref: Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. PMID: 23007710 Ref: Etiology and oncogenesis of pancreatic carcinoma. PMID: 23213974 Ref: CAR's made it to the pancreas. PMID: 23243602 Ref: Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. PMID: 26225216 |
Ref: Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha7nAChR-mediated MUC4 upregulation. PMID: 22614008 Ref: EGFR and HER2 inhibition in pancreatic cancer. PMID: 23076814 Ref: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. PMID: 23211371 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. PMID: 23344532 Ref: Complexity of molecular alterations impacts pancreatic cancer prognosis. PMID: 23355925 Ref: Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. PMID: 23378339 Ref: Outlier kinase expression by RNA sequencing as targets for precision therapy. PMID: 23384775 Ref: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. PMID: 23422754 Ref: Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. PMID: 23441129 Ref: The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. PMID: 23887057 Ref: Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. PMID: 23933441 Ref: Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. PMID: 24003140 Ref: Clinical and molecular characterization of HER2 amplified-pancreatic cancer. PMID: 24004612 Ref: Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. PMID: 24186057 Ref: Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. PMID: 24791013 |
Ref: In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery. PMID: 24038924 Ref: Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. PMID: 24164699 Ref: MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-kappaB signaling in pancreatic cancer. PMID: 24240113 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells. PMID: 24448235 Ref: A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. PMID: 24643470 Ref: Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into the presence of the transcript variant of MUC4. PMID: 24676527 Ref: Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. PMID: 24810090 Ref: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. PMID: 24884523 Ref: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. PMID: 24928736 Ref: Loss of stromal caveolin-1 expression: a novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer. PMID: 24949874 Ref: Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. PMID: 24971005 Ref: Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. PMID: 25117978 Ref: Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. PMID: 25195596 Ref: HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. PMID: 25216528 Ref: MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. PMID: 25277192 Ref: IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. PMID: 25941587 Ref: HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. PMID: 25941588 |
Ref: Overexpression of proCOL11A1 as a stromal marker of breast cancer. PMID: 25005174 Ref: SOX9 regulates ERBB signalling in pancreatic cancer development. PMID: 25336113 Ref: Prognostic value of increased HER2 expression in cancers of pancreas and biliary tree. PMID: 25416598 Ref: mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. PMID: 25442249 Ref: Examination of HER3 targeting in cancer using monoclonal antibodies. PMID: 25564668 Ref: Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. PMID: 25686822 Ref: Whole genomes redefine the mutational landscape of pancreatic cancer. PMID: 25719666 Ref: First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. PMID: 25805799 Ref: The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. PMID: 25890497 Ref: Nanoparticle formulation of ormeloxifene for pancreatic cancer. PMID: 25890768 Ref: Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. PMID: 25896973 Ref: Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. PMID: 25918250 Ref: Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. PMID: 25992771 Ref: Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. PMID: 26035354 Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. PMID: 26287187 Ref: Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. PMID: 26320869 |
Ref: Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. PMID: 26495780 Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. PMID: 26668065 Ref: A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PMID: 26808546 Ref: Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma. PMID: 26851005 Ref: Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis. PMID: 26897036 Ref: Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. PMID: 26998056 Ref: Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PMID: 27070783 Ref: Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. PMID: 27187683 Ref: Combined targeting of TGF-beta, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. PMID: 27267807 Ref: Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. PMID: 27613577 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer. PMID: 27871278 Ref: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. PMID: 27974798 |
Ref: Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. PMID: 27974697 Ref: Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway. PMID: 28674429 Ref: Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. PMID: 28736628 Ref: Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. PMID: 28801248 Ref: Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. PMID: 28903367 Ref: Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer. PMID: 29172998 |
Ref: Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. PMID: 29157747 Ref: PRDM14 directly interacts with heat shock proteins HSP90alpha and glucose-regulated protein 78. PMID: 29178343 Ref: Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens. PMID: 29284349 Ref: MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. PMID: 29467405 Ref: Single- and two-photon imaging of human micrometastases and disseminated tumour cells with conjugates of nanobodies and quantum dots. PMID: 29545609 Ref: Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. PMID: 29670173 Ref: A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. PMID: 29757973 Ref: Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. PMID: 30121627 Ref: Harnessing the Immune System in Pancreatic Cancer. PMID: 30128712 Ref: Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report. PMID: 30200073 Ref: Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis. PMID: 30227250 Ref: Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. PMID: 30341213 Ref: Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. PMID: 30373904 Ref: Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. PMID: 30384408 |